Back to Results

Arbutus Biopharma Corp (ABUS)

Featured in Financially Strong Value High-Growth Small-Cap Stocks

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on developing therapies for infectious diseases in the United States. Its main pipeline targets chronic hepatitis B and includes Imdusiran, a GalNAc-conjugated, subcutaneously delivered RNAi candidate that is being studied in Phase 1 and Phase 2a trials, and AB-101, an oral PD-L1 inhibitor in Phase 1a/1b testing. The company says these programs are designed to suppress HBV antigens and help restore HBV-specific immune response. Arbutus also has a licensing agreement with Alnylam Pharmaceuticals related to LNP delivery technology. Founded in 2005 and formerly known as Tekmira Pharmaceuticals Corporation, the company adopted its current name in July 2015 and is headquartered in Warminster, Pennsylvania.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-ABUS
$5.30
5.9% Upside
Fair
$5.43
8.4% Upside
Fair
Excellent
0.0%
November 11, 2026
6.5x
3.8x
5.4x
991.2 M
901.2 M
0.4%
62.0%
36.2
-16.1%
Valuation • Fair Value

Arbutus Biopharma Corp (NASDAQ-ABUS) Fair Value by Valuation Model

Review the available estimates for Arbutus Biopharma Corp (NASDAQ-ABUS), including DCF Fair Value, Ben Graham Formula Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$5.30

Estimated upside of 5.9% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$6.48

Discounted cash flow valuation reference.

Ben Graham Formula Value

$8.58

Classic Ben Graham valuation formula reference.

EPV Fair Value

$8.14

Earnings power value estimate.

Comps Fair Value

$4.63

Comparable-company valuation reference.

Analyst Price Target

$5.43

Analysts imply upside of 8.4%.

How to read these valuation models

Use the 7 available valuation references for Arbutus Biopharma Corp (NASDAQ-ABUS) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Arbutus Biopharma Corp (NASDAQ-ABUS)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

181.7 M

Current operating scale indicator.

Revenue Forecast

180.7 M

Forward revenue estimate.

EBITDA

147.5 M

Current operating profitability reference.

EBITDA Forecast

76.839 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Arbutus Biopharma Corp (NASDAQ-ABUS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Arbutus Biopharma Corp (NASDAQ-ABUS)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Excellent

Positive financial-health read.

Piotroski Score

7

Relatively strong quality score.

Beneish M-Score

-1,000.00

No elevated caution signal from this screen.

Altman Z-Score

36.2

Relatively strong balance-sheet zone.

FCF / Net Income

-16.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Arbutus Biopharma Corp (NASDAQ-ABUS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Arbutus Biopharma Corp (NASDAQ-ABUS)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 11, 2026

Days to Earnings

50

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Arbutus Biopharma Corp (NASDAQ-ABUS), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Arbutus Biopharma Corp (NASDAQ-ABUS) Stock Forecast & Technical Outlook

Review Arbutus Biopharma Corp (NASDAQ-ABUS) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Arbutus Biopharma Corp (NASDAQ-ABUS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Arbutus Biopharma Corp (NASDAQ-ABUS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Arbutus Biopharma Corp (NASDAQ-ABUS) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Arbutus Biopharma Corp (NASDAQ-ABUS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Arbutus Biopharma Corp (NASDAQ-ABUS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Arbutus Biopharma Corp (NASDAQ-ABUS)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Arbutus Biopharma Corp (NASDAQ-ABUS) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Arbutus Biopharma Corp (NASDAQ-ABUS) Stock FAQ

Data-supported answers about Arbutus Biopharma Corp (NASDAQ-ABUS), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$5.30
Estimated upside 5.9%
Valuation Rating
Undervalued
Estimated upside of 5.9%
Analyst Target
$5.43
Implied upside 8.4%
Financial Health
Excellent
Current financial-health read

The current fair value estimate for Arbutus Biopharma Corp (NASDAQ-ABUS) is $5.30. This implies an estimated upside of 5.9% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 5.9% versus the current market price.

The available analyst price target for Arbutus Biopharma Corp (NASDAQ-ABUS) is $5.43. The analyst target implies estimated upside of 8.4%.

The current financial health read for Arbutus Biopharma Corp (NASDAQ-ABUS) is Excellent. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Arbutus Biopharma Corp (NASDAQ-ABUS) is November 11, 2026.

The latest available data indicates no current dividend yield for Arbutus Biopharma Corp (NASDAQ-ABUS).

The current P/E ratio listed for Arbutus Biopharma Corp (NASDAQ-ABUS) is 6.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Arbutus Biopharma Corp is 991.2 M.

The current enterprise value listed for Arbutus Biopharma Corp is 901.2 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Arbutus Biopharma Corp is NASDAQ-ABUS, and the stock is listed on NASDAQ.

Arbutus Biopharma Corp (NASDAQ-ABUS) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Arbutus Biopharma Corp is 0.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Arbutus Biopharma Corp is 62.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B